Wendy Hill is a clinical/regulatory expert with over 30 years experience in early nonclinical and clinical development and regulatory affairs in a variety of therapeutic areas including cancer, inflammation, infectious and cardiovascular disease. Wendy started her career as an epidemiologist in cancer research with the design of early phase clinical trials. She has successfully achieved approval for a number of CTA/IND filings and NDS/NDA filings in Canada, the US and Europe. Previous positions include Director of Research at Knoll Canada where she was instrumental in the clinical development of several human monoclonal antibodies, Senior Director, Clinical Research at GlycoDesign and R&D Director, Inflammation and Neurology at Amgen Canada. As a private consultant she has assisted biotechnology companies in preparing and executing strategic clinical and regulatory development plans for products and devices and in performing due diligence on products for potential investors. Wendy’s impressive track record in designing and implementing successful clinical studies reflects her creativity, highly effective team management skills and wealth of expertise as well as her commitment to quality.
